Literature DB >> 21060041

MUC16 as a sensitive and specific marker for epithelial downgrowth.

Vicky C Pai1, Ben J Glasgow.   

Abstract

OBJECTIVE: To compare immunohistochemical results of cytokeratin AE1/AE3, the traditional favored marker, with MUC16 and cytokeratin 19 for diagnostic sensitivity and specificity in epithelial downgrowth and control corneas.
METHODS: Immunohistochemical analysis was performed in 5 cases of epithelial downgrowth and 5 control specimens for MUC16, cytokeratin AE1/AE3, and cytokeratin 19 using the immunoperoxidase method. The mean percentages of reactive cells on the epithelium and endothelium were compared for each antibody using the Wilcoxon rank sum test. The sensitivity and specificity for each marker were compared.
RESULTS: All 3 antibodies showed high sensitivity (100%) in identifying epithelial downgrowth. However, the specificity was greatest for MUC 16 (100%) compared with cytokeratin 19 (80%) and cytokeratin AE1/AE3 (0%). None of the endothelial cells in any case showed reactivity to anti-MUC16 compared with anti-cytokeratin AE1/AE3 (mean [SD], 0.0% [0.0%] vs 17.4% [10.4%]; P = .008). Cytokeratin 19 was positive in every case of epithelial downgrowth but showed focal staining of the endothelium (3.4% of cells) in 1 control.
CONCLUSIONS: Antibodies for MUC16, cytokeratin AE1/AE3, and cytokeratin 19 are equally sensitive for downgrowth. However, anti-MUC16 showed superior specificity compared with anti-cytokeratin 19 or anti-cytokeratin AE1/AE3 in this study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060041      PMCID: PMC4898885          DOI: 10.1001/archophthalmol.2010.268

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  26 in total

1.  Cytokeratin and vimentin heterogeneity in human cornea.

Authors:  M Kasper; P Stosiek; B Lane
Journal:  Acta Histochem       Date:  1992       Impact factor: 2.479

2.  Epithelial downgrowth following Descemet's-stripping automated endothelial keratoplasty.

Authors:  B Michael Walker; Holly B Hindman; Katayoon B Ebrahimi; W Richard Green; Charles G Eberhart; Ivan Garcia; Albert S Jun
Journal:  Arch Ophthalmol       Date:  2008-02

3.  Exfoliative epitheliopathy of bullous keratopathy with breaches in the MUC16 Glycocalyx.

Authors:  Ben J Glasgow; Oktay K Gasymov; Richard C Casey
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-06       Impact factor: 4.799

4.  Cytokeratins 8 and 18 in adult human corneal endothelium.

Authors:  Stanislava Merjava; Ales Neuwirth; Vaclav Mandys; Katerina Jirsova
Journal:  Exp Eye Res       Date:  2009-05-04       Impact factor: 3.467

5.  Clinical, electron microscopic, and monoclonal antibody studies of intraocular epithelial downgrowth.

Authors:  M M Rodrigues; J H Krachmer; T T Sun
Journal:  Trans Am Ophthalmol Soc       Date:  1986

6.  An immunohistochemical analysis and comparison of posterior polymorphous dystrophy with congenital hereditary endothelial dystrophy.

Authors:  Glenn C Cockerham; Nora V Laver; Ahmed A Hidayat; Deborah L McCoy
Journal:  Cornea       Date:  2002-11       Impact factor: 2.651

7.  Immunohistochemical pathology of the corneal endothelium in iridocorneal endothelial syndrome.

Authors:  L W Hirst; J Bancroft; K Yamauchi; W R Green
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-04       Impact factor: 4.799

8.  Epithelial downgrowth after descemet stripping automated endothelial keratoplasty.

Authors:  Pawan Prasher; Orkun Muftuoglu; M L Hsiao; R W Bowman; R N Hogan; V Vinod Mootha
Journal:  Cornea       Date:  2009-07       Impact factor: 2.651

9.  Epithelial downgrowth after Descemet-stripping automated endothelial keratoplasty.

Authors:  Paul M Phillips; Mark A Terry; Stephen C Kaufman; Edwin S Chen
Journal:  J Cataract Refract Surg       Date:  2009-01       Impact factor: 3.351

10.  Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies.

Authors:  J Woodcock-Mitchell; R Eichner; W G Nelson; T T Sun
Journal:  J Cell Biol       Date:  1982-11       Impact factor: 10.539

View more
  4 in total

1.  A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Authors:  Mythili Koneru; Roisin O'Cearbhaill; Swati Pendharkar; David R Spriggs; Renier J Brentjens
Journal:  J Transl Med       Date:  2015-03-28       Impact factor: 5.531

2.  Morphometrical, Morphological, and Immunocytochemical Characterization of a Tool for Cytotoxicity Research: 3D Cultures of Breast Cell Lines Grown in Ultra-Low Attachment Plates.

Authors:  Fernanda Malhão; Ana Catarina Macedo; Alice Abreu Ramos; Eduardo Rocha
Journal:  Toxics       Date:  2022-07-24

3.  Pseudo second anterior lens capsule during post-vitrectomy cataract surgery: A case report.

Authors:  Laura E Drew-Bear; Mya Abousy; Charles G Eberhart; J Fernando Arevalo; Ashley Behrens
Journal:  Am J Ophthalmol Case Rep       Date:  2022-09-06

4.  Impact of the controlled release of a connexin 43 peptide on corneal wound closure in an STZ model of type I diabetes.

Authors:  Keith Moore; Gautam Ghatnekar; Robert G Gourdie; Jay D Potts
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.